Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Meningeal Carcinomatosis 2Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 3Irinotecan 3tozuleristide 2selpercatinib 2lenvatinib 2gadobenic acid 2avelumab 2Radiation 2Paclitaxel 2Leflunomide 2Immunotherapy 2Gemcitabine 2Everolimus 2Cisplatin 2Carboplatin 2Cancer Vaccines 2Bevacizumab 2Adjuvants, Immunologic 2ridaforolimus 1regorafenib 1prinomastat 1pomalidomide 1perillyl alcohol 1pemigatinib 1pembrolizumab 1pamiparib 1omburtamab I-131 1irinotecan sucrosofate 1interferon gamma-1b 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Neoplasms × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡